Voltaren Gel is a nonsteroidal anti-inflammatory drug (NSAID) that is used to treat pain, inflammation, and fever. It relieves pain and reduces inflammation in the body. Voltaren Gel is available in a wide variety of forms, including tablets, patches, and gel. The most popular brand-name forms of Voltaren Gel are the gel, cream, and liquid. Voltaren Gel can be used for a number of conditions, including:
Voltaren Gel should be used with caution in patients with a history of gastrointestinal conditions, liver disease, or kidney disease.
If you have a history of gout, inflammatory bowel disease, or menstrual irregularities, you should not use Voltaren Gel. Gout medications are known to increase the risk of gout and inflammatory bowel disease, and anti-inflammatory drugs such as diclofenac (Voltaren) or aspirin are associated with an increased risk of gout. NSAIDs can exacerbate gout, so it is essential to inform your healthcare provider of all medications you are taking before starting Voltaren Gel. Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that is used to treat pain, inflammation, and fever. Diclofenac is available in many brand-name forms, including Voltaren Gel. The most popular brand-name forms of diclofenac include the gel, cream, and liquid.
Voltaren Gel should be used with caution in patients with a history of gout or inflammatory bowel disease.
The information provided on this page is not a substitute for professional medical advice, diagnosis, or treatment. It is recommended for guidance only should you make any decisions based on uncertain information. If you have any questions or concerns, please talk to your doctor.
Read this Patient Information Leaflet if you are unsure if a medicine is right for you. If you are looking to buy anti-inflammatory medicines for children, please read this information carefully. The information on this page is not intended to be a substitute for professional medical advice, diagnosis, or treatment. If you have or have ever had a medical condition, including a history of gout, inflammatory bowel disease, or menstrual irregularities, you should talk to a doctor before taking Voltaren Gel. Before you start taking a medicine, you should always read the Patient Information Leaflet for a full list of medicines that may interact with it. You should also read the leaflet that comes with the medicine. You may need to talk to your doctor about the risks and benefits of taking Voltaren Gel. If you are buying anti-inflammatory medicines online, you are probably buying medicines from a trusted online pharmacy. This is because the online pharmacy may not be reputable and because of the risks to your health. You can check the website of this online pharmacy or check their.The information on this page is not a substitute for professional medical advice, diagnosis, or treatment.Voltaren is a nonsteroidal anti-inflammatory (NSAID) derivative of Diclofenac, a well-known ingredient of the gout joint pain medication. It is commonly used to treat osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain, and osteoarthritis in adults and adolescents with both sexes and children in appropriate doses and duration of activity. The cardiovascular effects of Voltaren are being investigated as an alternative treatment option for patients with arthritis, particularly in the management of acute symptoms associated with arthritis.
The global Voltaren market is anticipated to experience significant growth, driven by several key factors. As of 2023, the market size was valued at USD 3.25 billion[5].
The global Voltaren market is anticipated to witness significant growth in the from 2024 to 2031[8].
The Voltaren market is projected to grow at a CAGR of 6.3% from 2024 to 2031 as defined by the US Government[5].
The increasing convenience and accessibility of products such as Voltaren have driven market growth in this and other key regions. These factors include the growing popularity of Voltaren products and the growing awareness of arthritis treatment options through social media and direct-to-consumer media[9].
The Voltaren market is segmented by product type and is segmented into tablets, capsules, sprays, andules. The market participants are further categorized into three product groups:
There is no particular limit on the number of product type segments in the listed product information tier. The maximum information tier for the listed product information is five years.
The format of the listed information is displays with the most popular products categorized by product type. There are also individual product information types for every product type sold.
WIPO Arbitration and Mediation Center
ADMINISTRATIVE PANEL DECISION
Foxtas Pharma Limited v. N. E. C. D., Inc.
Case No. D2006-0432
1. The Parties
The Complainant is Foxtas Pharma Limited, New York, New York, New York, United States of America, represented by United States of America.
The Respondent is N. D., Inc., of New York, New York, United States of America.
2. The Domain Name and Registrar
The disputed domain name <diclugravenin.com> is registered with eTrade.com.
3. Procedural History
The Complaint was filed with the WIPO Arbitration and Mediation Center (the “Center”) on September 8, 2006. On September 9, 2006, the Center transmitted by email to eTrade.com a request for registrar verification in connection with the disputed domain name. On September 15, 2006, eTrade.com transmitted by email to the Center its verification response confirming that Respondent is listed as the registrant and providing the contact details. The Center verified that the Complaint satisfied the formal requirements of the Uniform Domain Name Dispute Resolution Policy (the “Policy”), the Rules for Uniform Domain Name Dispute Resolution Policy (the “Rules”), and the WIPO Supplemental Rules for Uniform Domain Name Dispute Resolution Policy (the “Supplemental Rules”).
In accordance with the Rules, paragraphs 2(a) and 4(a), the Center formally notified the Respondent of the Complaint, and the proceedings commenced on September 16, 2006. In accordance with the Rules, paragraph 5(a), the due date for Response was October 2, 2006. The Respondent did not submit any response. Accordingly, the Center notified the Respondent’s default on October 3, 2006.
The Center appointed Daniel A. DeWitt as the sole panelist in this matter on October 16, 2006. The Panel finds that it was properly constituted. The Panel has submitted the Statement of Acceptance and Declaration of Impartiality and Independence, as required by the Center to ensure compliance with the Rules, paragraph 7.
4. Factual Background
Foxtas Pharma Limited, a Japanese multinational pharmaceutical corporation, manufactures and markets prescription painkillers and other non-prescription products under the trade names Flector, Voltaren and Theraphil, under the trade names Vardafil, and Flector XR. The Complainant, in a letter dated July 17, 1999, informed the Center that in its Internet domain name registration on the Complainant’s website, it listed the subject of this litigation. The Complainant is the owner of the Complainant’s Internet domain name registered on the Complainant’s website, in which it has registered the domain name. The Complainant has registered the disputed domain name <diclugravenin.com> with the Registrar. The Complainant has also registered the disputed domain name <diclugravenin.com> with the Registrar. The Respondent has not been notified of the Complaint, but has been given an opportunity to submit a response in accordance with the Rules, paragraph 5(a).
The Panel finds that the Respondent’s registration of the disputed domain name in connection with the disputed domain name was timely and properly performed. In the Complaint, the Complainant did not provide the disputed domain name to the Center, but instead to the Respondent. The Respondent did not provide the disputed domain name to the Center. The Complainant has not complained of the Complaint and has not been served with the Complaint, nor has the Center ever notified the Respondent of its decision to provide the disputed domain name to the Complainant.
The Center has submitted a Statement of Acceptance and Declaration of Impartiality and Independence, as required by the Rules, paragraph 7.
5.
Voltaren
Regular price$20.99 CAD
Sale price
Unit price/perSaleSold outCouldn't load pickup availability
RefreshDescription:Voltaren Emulgel Extra Strength Gel is formulated to provide relief for acute, localized, minor muscle or joint injuries and contains diclofenac diethylamine, which is a non-steroidal anti-inflammatory drug. This gel has a mild scent that disappears as the gel penetrates the skin and can be applied every 12 hours.
Indications:For relief of aches and pain associated with acute, localized minor muscle or joint injuries such as sprains, strains, or sports injuries (e.g. ankle sprain, shoulder strain, back muscle pain, etc.)
Dosage for Adults Aged 18 to 65 Years:
Medicinal Ingredients (per gram):
Non-medicinal Ingredients:
Warning:
This product is also available in:
Product DIN: 02393190. Please read labels and package inserts for all product details. Always read and follow labels and package inserts before use. Results may vary.
-----
Please note: Due to provincial pharmacy regulations, this product cannot be shipped to customers in Quebec.
Share ShareWe will send you a email with a copy of your response to our physician/doctor for review. We will ask you to leave a response on the email. our physician/doctorVoltaren Emulgel Extra Strength is an antibiotic gel that contains diclofenac diethylamine, which is a non-steroidal anti-inflammatory drug. It is used to treat inflammation and pain, to relieve muscle aches, and to treat some forms of back pain.
Stade de France Pharmacy